David McWilliams, CEO of PharmaFrontiers Corp, recently gave an interview with StreetIQ.com on August 25, 2005. The mp3 audio file of the interview can be found here
. While the interview is targeted towards investors and not a scientific audience, there is still some very encouraging news none-the-less. During the interview, David McWilliams indicates that they are obtaining a 90% reduction in relapses! In addition, he states that 40% of their patients have improved physically with an improvement in disability scores ranging from 0.5 to 3 points on a 10 point scale within 6 months, and that the treatment is "stopping the progression of the disease!"